Alcon trims guidance, sees $100 mln hit from U.S. tariffs

Investing.com -- Alcon AG (SIX:ALCC) (NYSE:ALC) lowered its 2025 sales guidance on Tuesday, citing the continued drag from U.S. tariffs.

The Swiss-American eye-care company, which generates almost half of its revenue in the U.S., now expects annual net sales of $10.3 to $10.4 billion, down from the $10.4 to $10.5 billion range it projected in May.

The company said the full-year tariff impact is likely to be about $100 million, though it aims to soften the blow through operational adjustments and currency effects.

U.S. tariffs on goods from Switzerland currently stand at 39%, among the highest faced by any Western nation. In 2024, Alcon derived 46% of its sales from the U.S. market.

Second-quarter revenue increased 4% to $2.58 billion, below the $2.63 billion analysts expected, according to LSEG data. The group noted softer demand for its surgical products in the first half of the year.

Diluted earnings per share (EPS) for the quarter were $0.35, while core diluted earnings per share came in at $0.76.

For the first half of the year, the company reported a revenue of $5.02 billion. It generated $889 million in operating cash flow and $681 million in free cash flow for the period.